
Most patients with pancreatic cancer present with zzso disease and have a dismal zzso Despite the proven albeit modest benefits of zzso demonstrated over a decade ago, subsequent advances have been slow, suggesting it may be time to take a different zzso It is thought that some key characteristics of pancreatic cancer, such as the zzso restricted zzso and hypoxic environment, may prevent the delivery of chemotherapy to the zzso thereby explaining the limited benefits observed zzso Moreover, there is evidence to suggest that the zzso is not only a mechanical barrier but also constitutes a dynamic compartment of pancreatic zzso that is critically involved in zzso formation, progression and zzso Thus, targeting the zzso and the zzso represents a promising therapeutic zzso Currently, several zzso agents are entering clinical zzso Among these, zzso appears promising since it combines zzso therapy with targeted delivery via its proposed ability to bind zzso on zzso and zzso zzso zzso data indicate that zzso with zzso and zzso results in zzso zzso increased zzso zzso and zzso zzso zzso and increased zzso zzso compared with either agent zzso Phase zzso study data also suggest that a high level of zzso activity can be achieved with this combination in pancreatic zzso This was recently confirmed in a Phase III study which showed that zzso plus zzso significantly improved overall survival zzso zzso and zzso survival zzso zzso versus zzso alone for the zzso treatment of patients with zzso pancreatic zzso 

